Market Size of Gynecology Drugs Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
CAGR | 6.20 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Gynecology Drugs Market Analysis
The gynecology drugs market is expected to register a CAGR of 6.2% over the forecast period.
- The COVID-19 pandemic considerably impacted the management of patients with gynecologic diseases during the initial pandemic. For instance, according to a study published by SAGE Journals in August 2022, the management of gynecological cancers suffered during the pandemic, partly due to lockdowns and partly due to directing resources to manage COVID-19 patients. It was also stated that modification of gynecological cancer management during the pandemic was recommended. Therefore, such instances indicated that the market witnessed slow growth during the pandemic. However, with the easing of restrictions and lockdowns and declining cases of COVID-19, the market was expected to witness considerable growth over the forecast period.
- The major factors driving the growth of the studied market include the increasing burden of gynecological diseases and the rise in healthcare awareness along with the increasing aging female population.
- The rising incidence of various gynecological diseases is projected to continue in the future, which is likely to fuel the demand for efficient treatment, driving the global gynecological drugs market over the forecast period. According to an article published by Cureus in August 2022, a study was conducted in India, which showed that the prevalence of polycystic ovary syndrome (PCOS) was 6.8% among the study participants. The source also stated that polycystic ovary syndrome is a very common health problem among adolescents and young girls. Thus, the high burden of such diseases is expected to boost the market growth.
- Moreover, according to the data published by the National Cancer Institute in January 2022, the estimated number of new cervical cancer cases in 2022 was around 14,100 in the United States, which is around 0.7% up from previous years of all new cancer cases. Similarly, as per the report published by the American Cancer Society in January 2022, around 19,880 women were expected to receive a new diagnosis of ovarian cancer in 2022. Therefore, such a high prevalence of gynecology cancers is expected to fuel the demand for gynecology drugs, thereby propelling the market growth.
- Moreover, the rising developments by key market players are also enhancing the market growth. For instance, in May 2021, Myovant Sciences and Pfizer Inc. received approval from the United States Food and Drug Administration (USFDA) for MYFEMBREE, the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months.
- However, the high cost and stringent regulatory framework that delays the approval of products are likely to impede market growth over the forecast period.
Gynecology Drugs Industry Segmentation
Gynecological drugs are used to treat ailments related to the female reproductive system. A major shift in the lifestyles of women led to a rise in the prevalence of gynecological disorders affecting the functioning of the uterus, ovaries, and appendages.
The gynecology drugs market is segmented by therapeutics (hormonal therapy and non-hormonal therapy), by indication (gynecology cancers, menopausal disorder, polycystic ovary syndrome, contraception, and other indications), by distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.
The report offers the value (in USD) for the above segments.
By Therapeutics | |
Hormonal Therapy | |
Non-hormonal Therapy |
By Indication | |
Gynecology Cancers | |
Menopausal Disorder | |
Polycystic Ovary Syndrome | |
Contraception | |
Other Indications |
By Distribution Channel | |
Hospital Pharmacies | |
Retail Pharmacies | |
Online Pharmacies |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Gynecology Drugs Market Size Summary
The gynecology drugs market is poised for significant growth over the forecast period, driven by an increasing burden of gynecological diseases and heightened healthcare awareness. The market experienced a slowdown during the COVID-19 pandemic due to resource allocation towards managing the virus, but is expected to recover as restrictions ease. The rising incidence of conditions such as polycystic ovary syndrome and gynecological cancers is anticipated to boost demand for effective treatments. Key market players are actively developing and launching new products, such as Myovant Sciences and Pfizer Inc.'s MYFEMBREE, which received FDA approval for managing heavy menstrual bleeding. However, challenges such as high costs and a stringent regulatory environment may hinder market expansion.
The non-hormonal therapy segment is expected to experience robust growth, attributed to its proven efficacy and reduced side effects compared to hormonal alternatives. Ongoing studies and clinical trials, such as Bayer's Phase III program for elinzanetant, are enhancing the understanding and application of non-hormonal therapies in treating gynecological conditions. North America is projected to hold a significant market share, supported by advanced healthcare infrastructure and a high prevalence of gynecological diseases. The region's market growth is further bolstered by government initiatives and early product launches. The competitive landscape is characterized by the presence of major players like Allergan Plc, Pfizer Inc, and AbbVie Inc, who are employing strategies such as product launches and acquisitions to strengthen their market positions.
Gynecology Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Burden of Gynecological Diseases
-
1.2.2 Rise in Healthcare Awareness Along with Increasing Ageing Female Population
-
-
1.3 Market Restraints
-
1.3.1 High Cost and Stringent Regulatory Framework that Delays the Approval of the Drugs
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD)
-
2.1 By Therapeutics
-
2.1.1 Hormonal Therapy
-
2.1.2 Non-hormonal Therapy
-
-
2.2 By Indication
-
2.2.1 Gynecology Cancers
-
2.2.2 Menopausal Disorder
-
2.2.3 Polycystic Ovary Syndrome
-
2.2.4 Contraception
-
2.2.5 Other Indications
-
-
2.3 By Distribution Channel
-
2.3.1 Hospital Pharmacies
-
2.3.2 Retail Pharmacies
-
2.3.3 Online Pharmacies
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Gynecology Drugs Market Size FAQs
What is the current Global Gynecology Drugs Market size?
The Global Gynecology Drugs Market is projected to register a CAGR of 6.20% during the forecast period (2024-2029)
Who are the key players in Global Gynecology Drugs Market?
Ferring Holding SA, TherapeuticsMD Inc., AbbVie Inc., Pfizer Inc. and GSK plc are the major companies operating in the Global Gynecology Drugs Market.